intranasal route raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-17 and is reviewed periodically as new material appears.
Semax 是一种人工合成的七肽，氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro，单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物，但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly，Semax 替换了中间两个残基，并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
研究兴趣主要集中在神经营养因子相关的路径上，包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升，但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验，人体对照研究数量有限。因此，该化合物的作用机制在文献中属于活跃讨论，而非已经确立的定论。
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
| Property | Value | Notes |
|---|---|---|
| 化学类别 | 合成七肽 | ACTH(4-10) 结构类似物 |
| 氨基酸序列 | Met-Glu-His-Phe-Pro-Gly-Pro | 单字母写作 MEHFPGP |
| 分子量 | 约 813.9 Da | 随确切形式和盐型略有变化 |
| 常见同义词 | ACTH(4-10) 类似物 | 俄语文献称 Семакс |
| 开发来源 | 俄罗斯 | 二十世纪八十年代 |
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
When the news of the curative properties of penicillin broke, Fleming revelled in the publicity. Journalists told a familiar story of a lone British scientist and a serendipitous discovery. The British medical historian Bill Bynum wrote:The discovery and development of penicillin is an object lesson of modernity: the contrast between an alert individual (Fleming) making an isolated observation and the exploitation of the observation through teamwork and the scientific division of labour (Florey and his group). The discovery was old science, but the drug itself required new ways of doing science. In 1943, the Nobel committee received a single nomination for the Nobel Prize in Physiology or Medicine for Fleming and Florey from the British biochemist Rudolph Peters. The secretary of the Nobel committee, Göran Liljestrand, made an assessment of Fleming and Florey in the same year, but little was known about penicillin in Sweden at the time, and he concluded that more information was required. The following year, there was one nomination for Fleming alone and one for Fleming, Florey and Chain. Liljestrand and Nanna Svartz considered their work, and while both judged Fleming and Florey equally worthy of a Nobel Prize, the Nobel committee was divided, and decided to award the prize that year to Joseph Erlanger and Herbert S. Gasser instead. In 1945 there were a large number of nominations for Florey and Fleming or both, and one for Chain, from Liljestrand, who nominated all three.
=== RNP-MaP site identification === RNP-MaP sites are defined as protein bound nucleotides. SDA and UV treated and UV only treated sample sequence reads are aligned and mutations are counted using ShapeMapper2 software. The SDA or RNP-MaP reactivity for a nucleotide is the ratio of the crosslinked (SDA and UV treated) mutational frequency to the un-crosslinked (UV only) mutation frequency. Using differential mutational signatures, RNP-MaP sites are identified based on universal normalization factors and thresholds on each RNA nucleotide (U, A, C, and G) derived from analysis of ribonucleoproteins of known structure. A nucleotide is identified as a RNP-MaP site if it passes three filters:
Douglas Carlyle Cameron (born March 22, 1957) is an American engineer, inventor, and investor. He is a senior managing director for the U.S.-China Green Fund. He is on the board of the Foundation for Food and Agriculture Research (FFAR) and is a technical and business advisor to organizations including the VTT (Finland), and the Center for Bioenergy Innovation (USA).
Sources: en.wikipedia.org
Other tools focus on applying structured constraints to inputs, restricting outputs to predefined parameters, or using real-time monitoring mechanisms to identify and address vulnerabilities. These efforts aim to ensure that AI systems are designed with safety and ethical considerations at the forefront, particularly as their use becomes increasingly widespread in critical applications.
There are many methods to investigate protein–protein interactions which are the physical contacts of high specificity established between two or more protein molecules. This process typically involves electrostatic forces and hydrophobic effects. Each of the approaches has its own strengths and weaknesses, especially with regard to the sensitivity and specificity of the method. A high sensitivity means that many of the interactions that occur are detected by the screen. A high specificity indicates that most of the interactions detected by the screen are occurring in reality.
Ketones in the urine or blood, as detected by urine strips or a blood ketone testing meter, may indicate the beginning of diabetic ketoacidosis (DKA), a dangerous and often quickly fatal condition caused by high glucose levels (hyperglycemia) and low insulin levels combined with certain other systemic stresses. DKA can be arrested if caught quickly. Ketones are produced by the liver as part of fat metabolism and are normally not found in sufficient quantity to be measured in the urine or blood of non-diabetics or well-controlled diabetics. The body normally uses glucose as its fuel and is able to do so with sufficient insulin levels. When glucose is not available as an energy source because of untreated or poorly treated diabetes and some other unrelated medical conditions, it begins to use fat for energy instead. The result of the body turning to using fat instead of glucose for energy means ketone production that is measurable when testing either urine or blood for them. Ketone problems that are more serious than the "trace or slight" range need immediate medical attention; they cannot be treated at home. Veterinary care for ketosis/ketoacidosis can involve intravenous (IV) fluids to counter dehydration, when necessary, to replace depleted electrolytes, intravenous or intramuscular short-acting insulin to lower blood glucose levels, and measured amounts of glucose or force feeding, to bring the metabolism back to using glucose instead of fat as its source of energy.
Sources: en.wikipedia.org
Due to Monster's partnership and partial ownership by The Coca-Cola Company, Bang is now distributed through Coca-Cola's distribution network. The Chapter 11 proceedings of Vital Pharmaceuticals, Inc. and six affiliated debtors (Case No. 22-17842 ) were filed in the United States Bankruptcy Court for the Southern District of Florida before Judge Peter D. Russin. Berger Singerman LLP, led by partner Jordi Guso, and Latham & Watkins LLP served as co-counsel to the debtors, with Rothschild & Co retained as investment banker and Huron Consulting Group as financial advisor. The proceedings attracted significant creditor participation, with firms such as Conrad & Scherer LLP, Pachulski Stang Ziehl & Jones LLP, Mark S. Roher, P.A. of South Florida, and Bast Amron LLP representing various creditor interests and stakeholders throughout the sale process and plan confirmation. The brand's founder is a supporter of president Donald Trump, and has donated $250,000 to America First Action, a super PAC endorsed by Trump. Bang has been the subject of controversy for its attendance at Turning Point USA conferences, including a stunt in which the brand's marketers fired cash out of a "money cannon" towards the audience. The company also drew criticism for its response to the COVID-19 pandemic, ordering employees to attend a mandatory in-person meeting, a "dance party" promoting their Redline Noo-Fusion product, without proper social distancing or security protocols.
Deadlift – 400 kg (882 lb) (2005 Pojedynek Gigantów) Keg drop Deadlift – 295–350 kg (650–771 lb) x 6 lifts in 33.89 seconds (2005 World's Strongest Man) Keg drop Squat – 265–340 kg (584–750 lb) x 7 reps in 21.28 seconds (2007 World's Strongest Man - Group 4) Keg drop Squat – 260–360 kg (573–794 lb) x 7 reps in 27.53 seconds (2005 World's Strongest Man) (former world record) Log lift – 172 kg (379 lb) (2005 Met-Rx Grand Prix) Log lift (for reps) – 130 kg (287 lb) x 14 reps (2006 Moscow Grand Prix) Axle press (for reps) – 140 kg (309 lb) x 11 reps (2006 WSMC Poland) (World Record) Apollon wheel press – 166 kg (366 lb) x 4 reps (2004 Arnold Strongman Classic) Viking press – 150 kg (331 lb) x 12 reps (2007 Mohegan Sun Grand Prix) Kettlebell press – 80 kg (176 lb) x 8 reps (2009 Globe's Strongest Man) Atlas Stones – 5 stones weighing 115–155 kg (254–342 lb) on tall platforms in 21.09 seconds (2006 Strongman Super Series Moscow Grand Prix) (World Record) Ding carry – 160 kg (353 lb) for 90 metres (2005 World's Strongest Man) (World Record) Asia Stone / shield carry – 175 kg (386 lb) for 127.4 metres (2002 World's Strongest Man) (World Record) Africa Stone carry – 175 kg (386 lb) for 110 metres (2000 World's Strongest Man - Group 5) (World Record) Block carry – 180 kg (397 lb) for 80 metre course in 41.32 seconds (2002 Europe's Strongest Man) (World Record) Fridge carry (super yoke) – 410 kg (904 lb) for 20 metres in 15.29 seconds (2005 World's Strongest Man) Timber carry – 392 kg (864 lb) (40' ramp) in 22.93 seconds (Raw grip) (2006 Arnold Strongman Classic) Wheelbarrow carry (no straps) – 300 kg (661 lb) (25m course) in 15.50 seconds (2003 IFSA Finland Grand Prix) (World Record) Farmer's walk (no straps) – 150 kg (331 lb) per each hand for 60m course in 19.90 seconds (2006 Strongman Super Series Poland Grand Prix) (World Record) Farmer's walk (no straps) – 137.5 kg (303 lb) per each hand for 70m course in 22.48 seconds (2003 Strongman Super Series Finland Grand Prix) (World Record) Super Yoke – 360 kg (794 lb) for 20 meters in 7.66 seconds (2006 World Strongman Cup Federation, Poland) (World Record) Medicine Ball Toss – 23 kg (51 lb) for 4.88 meters (2004 Arnold Strongman Classic) Power Stairs – (225 kg (496 lb) total of 14 steps) – 40.94 seconds (2008 World's Strongest Man) (World Record) Power Stairs – (230 kg (507 lb) total of 23 shallow steps) – 26.33 seconds (2006 World's Strongest Man) (World Record) Power Stairs – (200 kg (441 lb), 230 kg (507 lb) & 250 kg (551 lb) total of 15 high steps) – 31.22 seconds (2004 Europe's Strongest Man) (World Record) Power Stairs – (225 kg (496 lb), 250 kg (551 lb) & 275 kg (606 lb) total of 15 steps) – 28.56 seconds (2005 Nautilus Grand Prix) (World Record) Tyre Flip – 380 kg (838 lb) Tyre x 8 flips - 20.81 seconds (2004 Holland Champions Trophy) and 400 kg (882 lb) Tyre x 8 flips - 22.87 seconds (2006 Moscow Grand Prix) (former world records) Flip & drag – 400 kg (882 lb) tyre x 4 flips and 300 kg (661 lb) anchor & chain drag for 30 meters – 39.01 seconds (2002 World's Strongest Man) (world record) Conan's wheel (Basque circle) – 360 kg (794 lb) 765° rotation (2006 World Strongman Cup Russia) (World Record) Conan's wheel (Basque circle) – 317.5 kg (700 lb) 1,203° rotation (2003 Strongman Super Series Holland Grand Prix) (World Record) Conan's wheel (Basque circle) – 300 kg (661 lb) 1,440° rotation (2002 World's Strongest Man - Group 5) (former world record) Train pull – 16,000 kg (35,274 lb) for 25 meter course in 30.78 seconds (2003 World's Strongest Man) (World Record) Truck pull – 24,000 kg (52,911 lb) for 20 meter course in 26.05 seconds (2003 IFSA Strongman World Record Breakers) (World Record) Plane pull – 40,000 kg (88,185 lb) for 25 meter course in 36.67 seconds (2008 World's Strongest Man) (World Record) During training: (Self-claims)
When model penises without a coronal ridge were used, less than half the artificial sperm was displaced, compared to penises with a coronal ridge. The presence of a coronal ridge alone, however, is not sufficient for effective semen displacement. It must be combined with adequate thrusting to be successful. It has been shown that the deeper the thrusting, the larger the semen displacement. No semen displacement occurs with shallow thrusting. Some have therefore termed thrusting as a semen displacement behaviour. The behaviours associated with semen displacement, namely thrusting (number of thrusts and depth of thrusts), and duration of sexual intercourse, have been shown to vary according to whether a male perceives the risk of partner infidelity to be high or not. Males and females report greater semen displacement behaviours following allegations of infidelity. In particular, following allegations of infidelity, males and females report deeper and quicker thrusting during sexual intercourse.
25 April – Bute House Agreement: Scotland's SNP–Green power sharing agreement is formally dissolved, meaning Humza Yousaf now leads a minority government. The Scottish Conservatives table a vote of no confidence in Yousaf, which is scheduled for the following week. Labour pledge to renationalise most rail services within five years if they win the next general election. At the High Court, leader of the Reclaim Party Laurence Fox is ordered to pay £180,000 in libel damages to former Stonewall trustee Simon Blake and drag artist Crystal. Home Secretary James Cleverly says he opposes attempts to reduce the time limit for abortion. 26 April – Humza Yousaf says he will not resign as first minister of Scotland despite facing a motion of no confidence in his government. Sadiq Khan apologises to the Chief Rabbi over comments he made during a discussion about Islamophobia. 27 April – Dan Poulter, MP for Central Suffolk and North Ipswich defects from Conservative to the Labour Party, citing the NHS crisis as his reason for doing so. TUV leader Jim Allister, whose party agreed a formal partnership with Reform UK for the upcoming general election, distances himself from remarks in which Reform's deputy leader, Ben Habib, suggested some migrants travelling to the UK in small boats should be left to drown. 28 April – BBC News reports that Yousaf had ruled out an electoral pact between the SNP and Alba Party after Alex Salmond suggested the party would support him in a vote of no confidence in the Scottish Parliament.
Sources: en.wikipedia.org
不是。Semax 是完全人工合成的七肽，自然界中没有对应的已知肽段。它的设计灵感来自促肾上腺皮质激素片段 ACTH(4-10)，但序列经过了替换和延长。
Semax 被描述为 ACTH(4-10) 的结构类似物，两者共享部分序列特征。它保留了该片段的部分神经相关活性方向，但去除了完整片段带来的激素释放效应。二者并非同一物质，也不能互相替代。
加入的 Pro-Gly-Pro 三肽被普遍认为能提升分子对蛋白水解酶的稳定性。这种设计让短肽在体内维持时间更长。具体延长的程度以及不同组织中是否一致，文献中仍存在不同报告。
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.